Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Metabolic Efficiency of Islet Graft to Intensive Insulin Therapy for Type 1 Diabetes's Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with type 1 diabetes or C-peptide negative diabetes Diabetes duration \> 5 years~* No residual insulin secretion (plasmatic basal and stimulated C-peptide \< 0.3 ng/ml)~* HbA1c considered acceptable by the selection committee~* Insulin needs \< 0.85 IU/kg/day~* Islet cell infusion after kidney graft~  * Patient with terminal renal failure and functional kidney graft for at least 6 months (creatinine clearance greater than or equal to 35 ml/min)~ * Patient whose glycaemic control obtained with insulin therapy could threaten kidney graft survival and/or significantly alter quality of life. This situation is assessed by a diabetologist~* Islet cell infusion only: patient with major glycaemic variability despite proper intensive insulin therapy, closely monitored by a diabetologist. Poor glucose control, assessed by a diabetologist, endangers the patient's life and/or significantly alters personal, social, professional and family quality of life. At least one of these criteria must be fulfilled :~  * Hypoglycaemia unawareness, blood glucose level \< 3mmol/L or 0.54 mg/L~ * At least 2 severe hypoglycaemia events (defined by the necessity of a third party's assistance) per year or a ketoacidosis requiring patient's hospitalization during the last year.~ * Impairment of quality of life or life-threat for patient or other persons, or progressive complications despite optimal insulin therapy~* Social Security membership or benefit from Social Welfare~Exclusion Criteria:~* Age\< 18 and \> 65~* Diabetes duration \< 5 years~* Criteria specifically related to the islet intraportal injection procedure: hemostasis problem, haemoglobin level \< 11g/dL for women and \<12g/dL for men, abnormalities of complete blood count, documented liver pathology (alkaline phosphatases, gamma GT, transaminases levels over twice normal values) ; pancreatitis history, gallbladder stones that could potentially migrate; HLA hyperimmunisation (PRA \>20%).~* Criteria related to diabetes complications :~  * Non-stabilized proliferating diabetic retinopathy~ * Creatininaemia \> 16 mg/dL~* Exclusion criteria non-specifically related to islet infusion: evolutive vascular disease, evolutive cardiopathy (especially myocardial infarction less than 6 months ago, cerebrovascular stroke less than 6 months ago, evolutive arteritis with trophic disorders) ; systemic infection including hepatitis C and HIV ; leuconeutropenia ; thrombocytopenia, non-stabilized neoplastic pathology ; pregnancy or project of pregnancy within the next 24 months ; poor therapeutic compliance~* Criteria related to immunosuppressive protocol : renal failure (glomerular filtration \< 35 ml/min/1.73 m²) and/or proteinuria \> 0.5 g/24h ; non-treated hyperlipidemia (LDL-C \> 130 mg/dL) ; blood pressure \> 160/100 mmHg~* Clinical insulin resistance : assessed by patient's weight, BMI and exogenous insulin requirements (BMI \> 30 kg/m² or insulin dose \> 0.85 UI/kg/day)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- immediate registration on islet graft list (Type: EXPERIMENTAL): group 1 'immediate registration on infusion waiting list' : patients who will be immediately registrated on islet cell infusion waiting list after randomization.~Intervention : Procedure/surgery (islet graft)
- delayed registration on islet graft list (Type: ACTIVE_COMPARATOR): group 2 'delayed registration on infusion waiting list' : patients who will be registrated 6 months later on islet cell infusion waiting list after randomization.~Intervention : Procedure/surgery (islet graft)

Based on this trial design, predict the completion outcome and termination type (if applicable).